Concert Pharmaceuticals Announces Pricing of Public Offering

Concert Pharmaceuticals (NASDAQ:CNCE) announced the pricing of an underwritten public offering of 4,752,420 shares of its common stock at a public offering price of $9.92 per share.

As quoted in the press release:

In addition, and in lieu of common stock, Concert is offering to a certain existing investor pre-funded warrants to purchase up to an aggregate of 1,800,000 shares of common stock at a purchase price of $9.919 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Concert before deducting underwriting discounts and commissions and estimated offering expenses payable by Concert, are expected to be approximately $65.0 million. Concert has granted the underwriters a 30-day option to purchase up to an additional 982,863 shares of common stock at the offering price, less the underwriting discounts and commissions.

Click here to read the full press release.